The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Amelin A.V.

Pavlov First Saint Petersburg State Medical University

Skorobogatykh K.V.

«University Headache Clinic» LLC

Painful question

Authors:

Amelin A.V., Skorobogatykh K.V.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2024;(5): 44‑59

Read: 370 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Amelin AV, Skorobogatykh KV. Painful question. Non Nocere. New Therapeutic Journal. 2024;(5):44‑59. (In Russ.)

 
 
ЭндоКард
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Admission of a patient with headache. Migraine prophylaxis.

Authors:

Amelin A.V.

Pavlov First Saint Petersburg State Medical University

Skorobogatykh K.V.

«University Headache Clinic» LLC

Close metadata

References:

  1. The Guardian. Hou long do you get with your GP? Doctors’ consultation times – in data [Electronic resource]. Accessed: 15 April 2024. https://www.theguardian.com/society/datablog/2017/feb/10/how-long-do-you-get-with-your-gp-doctors-consultation-times-in-data
  2. Russian Interregional Society for the Study of Pain. International classification of headache (3rd edition, 2018) [Electronic resource]. Accessed: 15 April 2024. https://painrussia.ru/upload/pdf/%D0%9C%D0%9A%D0%93%D0%91-3.pdf
  3. Azimova YE, Amelin AV, Alferova VV, et al. Clinical guidelines “Migraine”. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1-3):4-36. (In Russ.) https://doi.org/10.17116/jnevro20221220134
  4. Dodick DW. Clinical clues and clinical rules: primary vs secondary headache. Advanced Studies in Medicine. 2003;3(6): S550–S555.
  5. Jenkins B. Migraine management. Aust Prescr. 2020 Oct;43(5):148-151.  https://doi.org/10.18773/austprescr.2020.047
  6. Filatova EG, Osipova VV, Tabeeva GR, et al. Diagnosis and treatment of migraine: Russian experts’ recommendations. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):4-14. (In Russ.). https://doi.org/10.14412/2074-2711-2020-4-4-14
  7. Amelin A.V., Ignatov Y.D., Skoromets A.A. et al. Migraine. Pathogenesis, clinic, pharmacotherapy. Manual for physicians. 4th ed. Moscow: MEDpress-Inform; 2017.
  8. Amelin A.V., Zaslavsky L.G., Skoromets A.A. Neurology. Pharmacotherapy without errors. Moscow: E-noto; 2023. – 656 p. 
  9. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011 Feb;31(3):301-315.  https://doi.org/10.1177/0333102410381145
  10. Tso AR, Goadsby PJ. Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention? Curr Treat Options Neurol. 2017 Aug;19(8):27.  https://doi.org/10.1007/s11940-017-0463-4
  11. Markham A. Erenumab: First Global Approval. Drugs. 2018 Jul;78(11):1157-1161. https://doi.org/10.1007/s40265-018-0944-0
  12. Russell FA, King R, Smillie SJ, et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014 Oct;94(4):1099-1142. https://doi.org/10.1152/physrev.00034.2013
  13. Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021 Jul;20(7):491-495.  https://doi.org/10.1038/d41573-021-00079-7
  14. Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015 Jun;79(6):886-895.  https://doi.org/10.1111/bcp.12591
  15. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010 May-Jun;2(3):256-265.  https://doi.org/10.4161/mabs.2.3.11641
  16. U.S. Securities and Exchange Commission. Teva Pharmaceutical Industries [Electronic resource]. Accessed: 15 April 2024. https://s24.q4cdn.com/720828402/files/doc_financials/2023/q1/Q1-2023-Form-10-Q-ADA-compliant.pdf
  17. Silberstein S, Lenz R, Xu C. Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know. Headache. 2015 Sep;55(8):1171-1182. https://doi.org/10.1111/head.12642
  18. Depre C, Antalik L, Starling A, et al. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina. Headache. 2018 May;58(5):715-723.  https://doi.org/10.1111/head.13316
  19. Tepper S, Fang J, Zhou L. Comparative Effectiveness of Erenumab versus Oral Preventive Medications among Migraine Patients: A US Claims Database Study. 2021. Neurology. 2021; Apr; 96 (15 Supplement). https://doi.org/10.1212/WNL.96.15_supplement.1821
  20. Vo P, Wen S, Martel MJ, Mitsikostas D, Reuter U, Klatt J. Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed. Cephalalgia. 2019 Apr;39(5):608-616.  https://doi.org/10.1177/0333102418801579
  21. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007 Feb;47(2):170-180.  https://doi.org/10.1111/j.1526-4610.2006.00684.x
  22. Silberstein SD, Lipton RB, Dodick DW, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009 Sep;49(8):1153-1162. https://doi.org/10.1111/j.1526-4610.2009.01508.x
  23. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ; TOPMAT-MIG 201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007 Jul;27(7):814-823.  https://doi.org/10.1111/j.1468-2982.2007.01326.x
  24. Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain. 2022 Jun 11;23(1):67.  https://doi.org/10.1186/s10194-022-01431-x
  25. Амелин А.В., Соколов А.Ю., Ваганова Ю.С. Мигрень, от патогенеза до лечения. М.: МЕДпресс-информ; 2022.
  26. Ilona Plug, Sandra van Dulmen, Wyke Stommel, Tim C. olde Hartman, Enny Das. Physicians’ and Patients’ Interruptions in Clinical Practice: A Quantitative Analysis. Ann Fam Med. 2022 Sep-Oct; 20(5): 423-429.  https://doi.org/10.1370/afm.2846
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.